Plaque Psoriasis Treatment: Finding the Right Plan for You
Plaque psoriasis can affect more than the skin. Itching, discomfort, and the time needed to manage treatment can interfere with sleep, work, and everyday life. As treatment options grow, finding an approach that fits a person’s health and routine can be just as important as choosing a medicine that helps clear the skin.
In a 13-part case-based discussion series, Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School of Medicine, and April Armstrong, MD, MPH, professor and chief of dermatology at UCLA, explored treatment decisions through three patient cases. The series also included the perspective of a person who has lived with psoriasis for about 30 years.
Their discussion covered when to consider medicines that work throughout the body, how to choose among biologic treatments, and why cost, convenience, and other health conditions matter. It was an expert discussion of individual cases, rather than a set of treatment recommendations for everyone. (Source: Bunick and Armstrong, Navigating Plaque Psoriasis Treatment: A Patient-Centered Approach to Therapy Selection)
When creams and ointments may not be enough
Plaque psoriasis is a condition that causes raised, scaly patches of skin. Doctors often consider how much of the body is affected when assessing its severity. This measurement is called body surface area, or BSA.
But the amount of skin involved does not tell the whole story. Psoriasis on the scalp, nails, palms, soles, or genitals can have a significant effect on daily life, even when it covers a smaller area.
Armstrong discussed recommendations from the International Psoriasis Council that take these high-impact areas into account when considering whether someone may be eligible for systemic treatment. These medicines work throughout the body, rather than only where they are applied. An inadequate response to creams or ointments is another factor. (Source: International Psoriasis Council recommendations, discussed in the Bunick and Armstrong series)
Treatment decisions also depend on how psoriasis affects a person’s quality of life and whether a treatment routine is manageable over time.
A physically demanding job and an impractical routine
In the first case, a 39-year-old roofing contractor had lived with plaque psoriasis for eight years. About 15% of his body surface was affected.
Sweating, sun exposure, and friction from his work equipment made his symptoms worse. He also had obesity and high blood pressure, along with a family history of heart disease at an early age. These factors added to the health considerations involved in choosing treatment.
Although psoriasis affected a substantial area of his skin, he had mainly relied on corticosteroids applied to the skin and used them inconsistently. Applying medicine over a large area can be difficult to maintain, particularly for someone with a physically demanding job. The experts discussed systemic treatment as an option to consider when the burden of applying medicine makes long-term control harder.
They also emphasized checking for other health conditions before choosing systemic treatment. These include psoriatic arthritis, a condition that can cause joint problems in people with psoriasis, as well as conditions affecting heart and metabolic health. (Source: Bunick and Armstrong, case-based psoriasis treatment series)
Choosing a biologic treatment
For people who have not previously used systemic treatment, there may be several options to discuss. Among them are biologics, medicines that target specific parts of the immune system.
When comparing biologics, the experts described three questions that matter:
- How quickly might the medicine begin to work?
- How much skin clearance might it provide?
- How well might its effects last over time?
These qualities can sometimes seem like trade-offs. Armstrong noted, however, that some newer biologic treatments may provide substantial skin clearance along with a response that lasts. Individual experiences can differ, and treatment choices also involve safety and other personal health factors. (Source: Bunick and Armstrong, Choosing First-Line Biologics for Treatment-Naive Plaque Psoriasis Patients)
The discussion also emphasized looking beyond the skin. Obesity, diabetes, heart disease risk factors, and other inflammatory conditions can all be relevant when a doctor and patient discuss a treatment plan.
Making treatment manageable for older adults
The second case involved a 72-year-old woman whose plaque psoriasis began later in life and affected about 12% of her body surface. Itching made it harder for her to walk and sleep. Osteoarthritis in her hands also made applying medicine to her skin difficult.
She had type 2 diabetes and had previously used corticosteroids applied to the skin, roflumilast, and the oral medicine apremilast. Changes in her daily routine meant she often missed doses of the oral treatment.
The experts discussed how physical limitations, the number of medicines a person takes, and day-to-day routines can all affect whether a treatment is practical. They also challenged the idea that age alone should rule out a biologic. Instead, they supported an individual safety assessment that considers overall health, other conditions, and other medicines.
For some people, a biologic given at longer intervals may be easier to fit into daily life. Injections given by a health care professional may also be helpful when using the hands or giving an injection at home is difficult.
Access matters, too. Insurance coverage and Medicare reimbursement can affect whether a treatment is affordable and available. The experts also discussed data on how long people continue using a group of biologics called interleukin-23 inhibitors, or IL-23 inhibitors. These medicines target an immune system signal involved in psoriasis. Their point was that a treatment needs to be both effective and practical enough to continue over time. (Source: Bunick and Armstrong, Access, Adherence, and Dosing Frequency in Older Psoriasis Patients)
When it is hard to stay on schedule
The third case featured a 34-year-old hospital administrator who worked night shifts and had trouble keeping up with her biologic treatment. Her psoriasis affected her scalp and nails, areas that can be particularly disruptive even when the total amount of affected skin is limited.
The experts said it is important to understand why a treatment is not providing enough relief before deciding that the medicine itself is not working. Missed doses or other difficulties with the treatment routine may play a role.
For medicines people inject themselves, challenges can include finding time in a changing schedule, feeling unsure about injection technique, storing the medicine, or feeling anxious about injections. Additional instruction, help with administration, or a different dosing schedule may sometimes address these barriers.
In this case, the patient ultimately chose tildrakizumab, an IL-23 inhibitor given every 12 weeks in a health care setting. That schedule better accommodated her demanding routine.
The experts also reviewed evidence on how tildrakizumab, secukinumab, and ustekinumab perform for psoriasis affecting the scalp and nails. They noted that treatment decisions can take these site-specific findings into account, along with a person’s other needs. (Source: Bunick and Armstrong, case-based psoriasis treatment series)
Even after a treatment is chosen, follow-up remains important. Symptoms can return between doses, and a medicine may become less effective over time. Reassessing both the response and the treatment routine can help guide later discussions.
One patient’s experience with cost and access
The series ended with the perspective of Keki Mody, an 83-year-old patient of Bunick who has managed psoriasis for about three decades. Mody described moving from medicines applied to the skin to biologic treatment.
His treatment journey was also shaped by other medical conditions, including monoclonal gammopathy of undetermined significance, or MGUS. This is a condition in which an unusual protein is found in the blood.
Insurance coverage and out-of-pocket costs were significant barriers to receiving effective treatment. After discussions with Bunick, Mody changed to tildrakizumab through Medicare Part B coverage and reported meaningful improvement in his psoriasis control.
His experience illustrates how affordability, a convenient schedule, and access to injections given by a health care professional can influence whether a treatment is workable over the long term. It is one person’s experience, and coverage and treatment responses can differ. (Source: Bunick and Armstrong, Navigating Plaque Psoriasis Treatment: A Patient-Centered Approach to Therapy Selection)
Finding a plan that fits
A psoriasis treatment plan involves more than the amount of skin affected. The experts’ discussion highlighted the importance of considering where psoriasis appears, how it affects daily life, other health conditions, previous treatments, and a person’s preferences.
It also showed why a treatment that is difficult to obtain, afford, or use consistently may not be a sustainable choice, even if it has the potential to clear the skin. Shared decision-making means discussing these practical concerns alongside potential benefits and safety with a doctor or dermatologist.
When to seek medical advice
If psoriasis symptoms are interfering with sleep, movement, work, or daily life, a doctor or dermatologist can help assess the situation. It is also important to seek professional advice about skin changes that are painful, bleeding, growing quickly, or showing signs of infection, or whenever you are unsure what is causing a skin problem.
This article is for information only and is not a substitute for medical advice. Treatment decisions and changes should be discussed with a doctor or dermatologist.
Sources
- Bunick CG, Armstrong A. Navigating Plaque Psoriasis Treatment: A Patient-Centered Approach to Therapy Selection. Dermatology Times. Accessed November 10, 2026.
- Bunick CG, Armstrong A. Choosing First-Line Biologics for Treatment-Naive Plaque Psoriasis Patients. Dermatology Times.
- Bunick CG, Armstrong A. Access, Adherence, and Dosing Frequency in Older Psoriasis Patients. Dermatology Times.
- International Psoriasis Council recommendations on systemic treatment eligibility, as discussed in the Bunick and Armstrong series.